Short Report Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition

Insulin-like growth factor (IGF)-I has cancer promoting activities. However, the hypothesis that circulating IGF-I concentration is related to risk of lymphoma overall or its subtypes has not been examined prospectively. IGF-I concentration was measured in pre-diagnostic plasma samples from a nested case–control study of 1,072 cases of lymphoid malignancies and 1,072 individually matched controls from the European Prospective Investigation into Cancer and Nutrition. Odds ratios (ORs) and confi-dence intervals (CIs) for lymphoma were calculated using conditional logistic regression. IGF-I concentration was not associated with overall lymphoma risk (multivariable-adjusted OR for highest versus lowest third 5 0.77 [95% CI 5 0.57– 1.03], p trend 5 0.06). There was no statistical evidence of heterogeneity in this association with IGF-I by sex, age at blood collection, time between blood collection and diagnosis, age at diagnosis, or body mass index ( p heterogeneity for all (cid:2) 0.05). There were no associations between IGF-I concentration and risk for specific BCL subtypes, T-cell lymphoma or Hodgkin lymphoma, although number of cases were small. In this European population, IGF-I concentration was not associated with risk of overall lymphoma. This study provides the first prospective evidence on circulating IGF-I concentrations and risk of lymphoma. Further prospective data are required to examine associations of IGF-I concentrations with lymphoma subtypes.

[1]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[2]  A. van den Berg,et al.  Insulin-Like Growth Factor 1 Receptor Is a Prognostic Factor in Classical Hodgkin Lymphoma , 2014, PloS one.

[3]  E. Riboli,et al.  Plasma 25-hydroxyvitamin D concentration and lymphoma risk: results of the European Prospective Investigation into Cancer and Nutrition. , 2013, The American journal of clinical nutrition.

[4]  K. Sfiridaki,et al.  Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma , 2013, Medical Oncology.

[5]  J. Manson,et al.  Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. , 2012, Blood.

[6]  R. Pieters,et al.  Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[8]  Jenny Donovan,et al.  Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. , 2012, Cancer research.

[9]  P. Clayton,et al.  Growth hormone, the insulin-like growth factor axis, insulin and cancer risk , 2011, Nature Reviews Endocrinology.

[10]  E. Jaffe,et al.  The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. , 2009, Hematology. American Society of Hematology. Education Program.

[11]  J. Cerhan,et al.  Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. , 2008, Blood.

[12]  D. Ludwig,et al.  Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis , 2006, Cancer Immunology, Immunotherapy.

[13]  A. Ochiai,et al.  Inhibition of bone‐derived insulin‐like growth factors by a ligand‐specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse , 2006, International journal of cancer.

[14]  D. Ribatti,et al.  Serum insulin‐like growth factor is not elevated in patients with early B‐cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression , 2006, European journal of haematology.

[15]  W. Willett,et al.  Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era , 2005, Cancer Causes & Control.

[16]  K. Anderson,et al.  Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. , 2003, Cancer research.

[17]  Jo Mitchell,et al.  Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study , 2003, Public Health Nutrition.

[18]  A. Waage,et al.  Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. , 2002, Blood.

[19]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[20]  R. Krajcik,et al.  Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. , 2002, Clinical chemistry.

[21]  S. Rudikoff,et al.  Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. , 2000, Blood.

[22]  E. Riboli,et al.  Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. , 2000, Journal of the National Cancer Institute.

[23]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.